Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Signaturefd LLC

Signaturefd LLC lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 11.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,640 shares of the biopharmaceutical company’s stock after selling 214 shares during the quarter. Signaturefd LLC’s holdings in Alnylam Pharmaceuticals were worth $386,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ALNY. Regeneron Pharmaceuticals Inc. acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $1,045,822,000. Raymond James Financial Inc. acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $65,295,000. Jennison Associates LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $61,160,000. Proficio Capital Partners LLC grew its position in shares of Alnylam Pharmaceuticals by 25,929.6% in the fourth quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock valued at $45,570,000 after purchasing an additional 192,916 shares during the period. Finally, Strategic Financial Concepts LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $41,529,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $253.60 on Friday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market cap of $32.83 billion, a PE ratio of -116.87 and a beta of 0.39. The firm has a 50-day simple moving average of $256.25 and a two-hundred day simple moving average of $259.51. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. The trade was a 81.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now owns 81,526 shares of the company’s stock, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,234 shares of company stock worth $19,958,097. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several research analyst reports. Canaccord Genuity Group lifted their target price on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. Sanford C. Bernstein dropped their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. HC Wainwright lifted their target price on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Chardan Capital reiterated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $304.26.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.